Citigroup downgrades Orange (NYSE:ORAN) from Buy to Neutral.
Immix Shares Rally On FDA Rare Pediatric Disease Tag For Cancer Program In Children
The FDA has granted Rare Pediatric Disease (RPD) designation to newly listed Immix Bio
Citigroup Downgrades Orange to Neutral
Citigroup downgrades Orange (NYSE:ORAN) from Buy to Neutral.
Related Posts
Analyst Ratings For Procter & Gamble
Over the past 3 months, 6 analysts have published their opinion on Procter & Gamble (NYSE:PG) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Analysts React To Qualtrics’ Q2 Results
Analysts continue to exude confidence in Qualtrics International Inc (NASDAQ:XM) with a hint of caution despite dismal Q3 guidance. JMP Securities analyst Patrick…